Ocular Therapeutix (OCUL) Consolidated Net Income (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Consolidated Net Income of -$79.5 million for Q2 2026, down 18.23% year-over-year from -$97.2 million in Q2 2025, and up 11.79% on a QoQ basis from -$90.1 million in Q1 2026.
Ocular Therapeutix (OCUL) Consolidated Net Income (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Consolidated Net Income for 14 years, with the latest figure at -$79.5 million in Q2 2026.
- Consolidated Net Income for Q2 2026 came in at -$79.5 million, down 18.23% year-over-year; the trailing twelve-month figure through Jun 2026 was -$302.7 million (down 35.84% YoY), and the FY2025 annual result was -$544.1 million, down 44.42% from the prior year.
- Consolidated Net Income advanced to -$79.5 million in Q2 2026, from -$90.1 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$16.9 million in Q4 2023 and troughed at -$90.1 million in Q1 2026.
- A 5-year average of -$43.0 million and a median of -$40.7 million in 2024 frame the typical range for Consolidated Net Income.
- The widest annual swing landed in 2022, when Consolidated Net Income gained 10.95%; it then plunged 190.56% in 2024.
- A 5-year view of Consolidated Net Income shows it stood at -$18.4 million in 2022, then rose by 8.12% to -$16.9 million in 2023, then plunged by 190.56% to -$49.0 million in 2024, then sank by 33.13% to -$65.2 million in 2025, then decreased by 21.77% to -$79.5 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were -$79.5 million in Q2 2026, -$90.1 million in Q1 2026, and -$65.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -79.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.45 Mn |
| Mar 31, 2026 | -90.07 Mn |
| Dec 31, 2025 | -62.44 Mn |
| Sep 30, 2025 | -67.97 Mn |
| Jun 30, 2025 | -67.20 Mn |
| Mar 31, 2025 | -63.08 Mn |
| Dec 31, 2024 | -56.97 Mn |
| Sep 30, 2024 | -43.57 Mn |
| Jun 30, 2024 | -40.75 Mn |
| Mar 31, 2024 | -40.66 Mn |
| Dec 31, 2023 | -27.06 Mn |
| Sep 30, 2023 | -21.43 Mn |
| Jun 30, 2023 | -21.81 Mn |
| Mar 31, 2023 | -23.75 Mn |
| Dec 31, 2022 | -20.79 Mn |
| Sep 30, 2022 | -23.06 Mn |
| Jun 30, 2022 | -21.54 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -15.53 Mn |
| Sep 30, 2021 | -21.18 Mn |